监管与产业动态· FiercePharma·· 16 hours agoPickScore76
GSK’s Jemperli scores FDA approval in rectal cancer, backed by high complete response rate - Fierce Pharma
In brief
FDA has approved GSK's Jemperli for rectal cancer, with the approval supported by data showing a high complete response rate.
Why it matters
The headline reports FDA approval of GSK's Jemperli in rectal cancer backed by a high complete response rate, letting readers compare it with existing data for this indication.
Source: 监管与产业动态